Pfizer said Friday it has stopped a late-stage study of its drug Lyrica as a potential treatment for HIV-related nerve pain. In the United States, Lyrica already is approved to treat nerve pain from diabetes, pain following shingles, fibromyalgia, and some seizures in adults with epilepsy. Pfizer has been studying Lyrica's potential use for HIV neuropathy, a condition involving nerve damage marked by burning pain that typically begins in the feet. However, an early analysis of study data found that pain improvements in treated patients were almost identical to those who received a placebo. The study did not raise any safety concerns; Pfizer plans further analysis of the results.
Back to other news for May 2012